Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand

Completed

• Conditions: Upper GIT Symptoms

• Registration Number: NCT00999063
• Lead Sponsor: AstraZeneca

Brief Summary

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-20
• Study First Submitted QC: 2009-10-20
• Study First Posted: 2009-10-21
• Study Start: 2009-12
• Primary Completion: 2011-02
• Study Completion: 2011-02
• Status Verified: 2011-03
• Last Update Submitted: 2011-03-30
• Last Update Posted: 2011-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4108

Inclusion Criteria

• Provision of informed consent prior to any study specific procedures
• Female or male aged at least 18 years
• Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria

• Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
• Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms

Secondary Outcome Measures

Name	Time	Method
Response to various treatments for patients who have been diagnosed of GERD

Trial Locations

Locations (1)

Research Site; 🇹🇭 Maung, Uttaradit, Thailand

Research Site

🇹🇭Maung, Uttaradit, Thailand